Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by LithLoveron Dec 02, 2020 10:07am
334 Views
Post# 32017250

Expecting a news release Friday

Expecting a news release FridayFor the first Offering:

TORONTO, ON / ACCESSWIRE / June 23, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") announces that it has today been issued a receipt by the Ontario Securities Commission in respect of its final prospectus dated June 22, 2020

The offering is expected to close on or about June 29, 2020

TORONTO, ON / ACCESSWIRE / June 29, 2020 / StageZero Life Sciences Ltd. (TSX:SZLS) (the "Company") is pleased to announce that is has closed its previously announced public offering of 66,176,100 units of the Company (the “Units”) at a price of $0.07 per Unit (the “Offering Price”) for aggregate gross proceeds of $4,632,327 (the “Offering”).

----------------
For the 2nd Offering:

TORONTO, ON / ACCESSWIRE / November 27, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") announces that it has today been issued a receipt by the Ontario Securities Commission in respect of its final prospectus dated November 26, 2020.

The offering is expected to close on or about December 4, 2020

<< Previous
Bullboard Posts
Next >>